Investment Summary
IP Group is a publicly listed, early-stage investor across the life sciences, cleantech and deeptech sectors. Each highly innovative company within its portfolio aims to have meaningful societal impact as well as generating substantial financial returns.
With over 20 years of experience and significant sector expertise, IP Group has a proven track record having backed three companies that have achieved billion-dollar valuations.
Investor Relations


What's the next 'big thing' within the portfolio?

Two companies that stand out are Hysata and Istesso. Hysata is the world's most efficient hydrogen electrolyser company and has made significant technological process this year. It has received an incredibly high level of commericial interest for such a young company.Istesso discovers and develops drugs for severe chronic diseases such as rheumatoid arthritis. Its current lead compound is in clinical trials and has shown promising signs that it may act as a cure to the underlying condition as well as just treating symptoms.

How can IP Group close the discount to NAV?

IP group expects significant inflection points from the underlying portfolio in the next 12-18 months to drive net asset value [NAV] per share. The capital allocation policy is to reinvest the majority of cash proceeds, with a smaller portion returned to shareholders. Since the adoption of this policy in 2021, IP Group has returned over £70m to shareholders.IP Group is also making significant strides to boost its investor relations efforts and tell the equity story worldwide.

What are the key challenges IP Group face and how might they be mitigated?

The two main challenges IP Group faces in the current market conditions are capital allocation and performance.In the difficult market conditions there are less exits and its hard to raise capital. This means IP Group must be prudent in managing its cash in terms of investments and returns to shareholders. IP Group is in a strong position, holding lots of cash and liquid assets. Despite difficult markets, IP Group portfolio companies need to continue to perform. In the near-term, this means successful clinical trials for some of the therapeutics companies and continued growth in their deeptech holdings.

What is IP Group's valuations approach for the underlying portfolio companies?

IP Group uses a conservative approach to valuations. Transparency and rigour around its approach is paramount. A substantial proportion of the portfolio is valued at a public share price, or the price of the last funding round. For a significant value of the portfolio, IP Group also gets an independent valuation produced. The Group’s external auditors typically sample more than 90% of the portfolio. For a deeper dive on the valuations approach, see the IP Group carousel below.

Are there any policy initiatives that might benefit IP Group?

In the UK there's an increasing discussion around long term capital supporting growth. This includes pension funds directing more capital into private assets and growth assets with the aim of stimulating the economy. IP Group is positioned well to benefit from this.


FY 2023 webinar
Watch Now
2023 review
Watch Now
executive summary
Watch Now
Valuations Deep Dive
Watch Now
Nuclear fusion
Watch Now
FY 2022 Results
Watch Now
Deeptech: AI
Watch Now
Investor Update 2022
Watch Now
AGM 2023
Watch Now
Approach to Impact
Watch Now



Executive interview
Watch Now
Nano Sequencing
Watch Now
ONT - Gene Sequencing
Watch Now
First Light Fusion Reactor
Watch Now
Watch Now
Breakthrough fusion reactor
Watch Now
Featurespace - Contis
Watch Now
Istesso 2021
Watch Now
Hinge Health
Watch Now
Watch Now




Portfolio company Hysata completes US$111m series B funding round
IP Group announces £20mn share buyback programme
Featurespace launches GenAI model for dealing with financial crime
IP Group boss: There have never been more stakeholders calling for Mansion House reforms
First Light achieves world first fusion result, proving unique new target technology
IP Group welcomes licensing agreement between Autifony and Jazz Pharmaceuticals
Google backs autonomous vehicle firm Oxa
IP Group plc Annual Results Release
Strong returns, significant cash realisations, capital recycled for growth alongside shareholder returns